Full Enrollment Achieved in LUMINATE Pivotal Trial Program for Novel Uveitis Therapy, Voclosporin

    EDMONTON, June 25 /CNW/ - (ISA:TSX): Isotechnika today announced their
partner, Lux Biosciences, has completed enrollment for the landmark LUMINATE
pivotal clinical trial program, which is investigating the use of voclosporin
(referred to as LUVENIQ(TM) by Lux) as a corticosteroid-sparing agent for the
treatment of patients with non-infectious uveitis. As planned, the three
randomized, placebo-controlled, double-masked studies together enrolled a
total of about 560 patients at 58 sites in 7 countries.
    "We are very pleased to have completed patient enrollment in an
expeditious manner in this largest-ever clinical trial program in
non-infectious uveitis, and thank our clinical investigators and their staff
for their enthusiasm and diligence," said Ulrich Grau, Ph.D., Lux Biosciences'
President and Chief Executive Officer. "As patients in the LUMINATE program
are treated and followed for six months, we expect to complete these studies
prior to year-end. If the studies are successful in demonstrating efficacy and
safety, we will seek regulatory approval for LUVENIQ(TM) in 2009."
    "The rapid progress of LUVENIQ(TM) is extremely exciting," stated Clemens
Kaiser, Isotechnika's Executive Vice President and Chief Marketing Officer.
"This is a substantial and near term revenue opportunity for Isotechnika."
    The three LUMINATE trials represent the first clinical development
program aimed at supporting regulatory approval of a corticosteroid-sparing
immunosuppressive agent in different types of sight-threatening,
non-infectious uveitis.

    About Uveitis
    Uveitis is an autoimmune disease characterized by chronic inflammation of
the eye. Uveitis is an under-diagnosed and under-recognized medical condition
that causes vision impairment, ocular pain, and loss of vision. Experts
estimate that 10% of new cases of blindness in the U.S. result from this
disease. Approximately 300,000 people suffer from uveitis in the United States
alone, the majority of whom are affected by anterior uveitis; Lux Biosciences
is targeting roughly a third of the disease population for potential
treatment. The only therapeutic class approved by the FDA for treatment of
uveitis is corticosteroids, which are burdened with multiple side effects,
such as osteoporosis, hyperglycemia, hypercholesterolemia, hypertension, mood
disturbances, and if applied chronically to the eye, cataract formation and

    About Isotechnika
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LUVENIQ(TM) by Lux) for the treatment of uveitis. Voclosporin
has also entered First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by the Company's partner, Atrium
Medical Corporation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com or www.SEDAR.com.

    Forward-Looking Statements
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E

For further information:

For further information: Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 (x247), Fax: (780) 484-4105, E-mail:
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Communications,
Isotechnika Inc., Phone: (780) 487-1600 (x243), Fax: (780) 484-4105, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890